During December, the number of short positions held in Wave Life Sciences Ltd. (NASDAQ: WVE) decreased by a sizeable amount. There were 1,500,000 shares available for a short sale as of December 30. This represents a decrease of 23.1% compared to the volume of 1,950,000 shares traded the day before. The current short-interest ratio is 2.2 days, calculated based on an average daily trading volume of 684,000 shares. This number was arrived at through the preceding calculation.
The most recent quarterly numbers for Wave Life Sciences (NASDAQ: WVE) were released on November 10, the 10th day of the month. Earnings per share for the company came in at $0.42 for the period, which was $0.06 more than the consensus estimate of $0.48. Wave Life Sciences had a return on equity that was negative by 1,038.84 percent and a negative net margin of 3,662.25%. Both of these figures were in red. The actual revenue for the company during the quarter was only $0.29 million, a significant drop from the $5.48 million that market experts anticipated the company would bring in during the period. The majority opinion among professionals in this field is that Wave Life Sciences will report a loss of $2.01 per share for the full year of 2018.
Hedge funds and other types of institutional investors have been responsible for recent buying and selling activity in WVE shares. Artal Group S.A. increased the amount of Wave Life Sciences stock it owned during the second quarter of the year by a factor of two hundred and zero. Artal Group S.A. now has a total of 3,000,000 shares of the company’s stock, which are currently valued at $9,750,000 after purchasing an additional 2,000,000 shares during the most recent quarter. These shares were purchased in their entirety. During the second quarter, FMR LLC achieved a 1,759.1% increase in the proportion of Wave Life Sciences stock it owned. FMR LLC now holds 1,238,026 shares of the company’s stock, valued at $4,024,000, following the acquisition of an additional 1,171,432 shares during the most recent period. During the third quarter, Point72 Asset Management L.P. paid approximately $3,733,000 to acquire a new position in Wave Life Sciences. During the second quarter, approximately 2,832,000 dollars were spent by Laurion Capital Management L.P. to acquire additional shares of Wave Life Sciences. During the second quarter, Millennium Management LLC increased the proportion of Wave Life Sciences it owns by a whopping 40.3%. Millennium Management LLC now owns 1,075,033 shares of the company’s stock, which are currently valued at $3,494,000 after the firm made an additional purchase of 308,975 shares during the most recent reporting period. 77.18% of the company’s shares are owned by institutional investors who have purchased large blocks of stock.
When trading began on Thursday, the price of a share of WVE’s stock was $4.81. The company’s market capitalization is currently sitting at $417.99 million, its price-to-earnings ratio stands at 2.12, and its beta value sits at 0.83. The moving average for the company over the past 50 days is $4.99, while the moving average over the last 200 days is $4.12. During the year, Wave Life Sciences experienced a 52-week low of $1.16 and a 52-week high of $7.12 in its share price.
Recent articles have been published by several research analysts discussing WVE shares.
SVB Leerink increased their target price on Wave Life Sciences from $2.00 to $7.00 in a research note published on Wednesday, December 14. They assigned the business the designation “market perform,” and the note was about the company. On October 12, a Wednesday, Wave Life Sciences was added to the research coverage that StockNews.com provides. They recommended that shareholders “hold” their shares of the company. In addition, the Royal Bank of Canada downgraded Wave Life Sciences from an “outperform” rating to a “sector perform” rating in a research note published on Friday, November 11.
Wave Life Sciences Ltd., a biotechnology company, employs synthetic chemistry in the production process of its one-of-a-kind pharmaceuticals to differentiate them from its competitors. This company’s primary goals include the research, development, and commercialization of therapies founded on nucleic acids as their active ingredients. On July 23, 2012, Gregory L. Verdine and Takeshi Wada began laying the groundwork for the company, and they concluded that its headquarters should be in Singapore.